Ming-chih Chang

TPQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Consensus of the Hematology Society of Taiwan on the management of paroxysmal nocturnal hemoglobinuria (PNH).

Consensus of the Hematology Society of Taiwan on the management of paroxysmal nocturnal hemoglobinuria (PNH).

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: August 16, 2025

Daratumumab-Based Combinational Therapy as Second-Line Treatment of Relapsed-Refractory Multiple Myeloma: A Single-Center Experience.

Daratumumab-Based Combinational Therapy as Second-Line Treatment of Relapsed-Refractory Multiple Myeloma: A Single-Center Experience.

Journal: Cancer reports (Hoboken, N.J.)

Published: August 12, 2024

Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system.

Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system.

Journal: PloS one

Published: April 13, 2024

The implication of serum HLA-G in angiogenesis of multiple myeloma.

The implication of serum HLA-G in angiogenesis of multiple myeloma.

Journal: Molecular medicine (Cambridge, Mass.)

Published: February 23, 2024

Safety and effectiveness of ruxolitinib in real-world patients with myelofibrosis: A 2-year observational study from Taiwan.

Safety and effectiveness of ruxolitinib in real-world patients with myelofibrosis: A 2-year observational study from Taiwan.

Journal: Leukemia research

Published: January 17, 2024

Analysis of mutation profiles in extranodal NK/T-cell lymphoma: clinical and prognostic correlations.

Analysis of mutation profiles in extranodal NK/T-cell lymphoma: clinical and prognostic correlations.

Journal: Annals of hematology

Published: July 18, 2023

NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan.

NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan.

Journal: International journal of hematology

Published: October 19, 2021

Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia.

Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia.

Journal: Blood cancer journal

Published: August 25, 2021

BAFF-driven NLRP3 inflammasome activation in B cells.

BAFF-driven NLRP3 inflammasome activation in B cells.

Journal: Cell death & disease

Published: June 11, 2020

Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan.

Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan.

Journal: Hematology (Amsterdam, Netherlands)

Published: December 19, 2018

Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma.

Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma.

Journal: Oncology reviews

Published: June 12, 2018

Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study.

Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study.

Journal: Therapeutic advances in hematology

Published: August 24, 2017

Showing 1-12 of 24

Last Updated: 09/26/2026